FindTrial
Sign In

Safety and Efficacy of Moderate Hypofractionated Radiotherapy After Radical Prostatectomy for Prostate Cancer

Safety and Efficacy of Moderate Hypofractionated Radiotherapy After Radical Prostatectomy for Prostate Cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600117251
Enrollment
Unknown
Registered
2026-01-21
Start date
2026-01-23
Completion date
Unknown
Last updated
2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate cancer

Interventions

Case series:Not applicable

Sponsors

West China Hospital of Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: (1) History of clinically localized prostate cancer confirmed by histologically and definitively treated with radical prostatectomy (2) Complete postoperative moderate hypofractionation treatment in our hospital.

Exclusion criteria

Exclusion criteria: (1) Those who have received pelvic radiotherapy or chemotherapy in the past; (2) Patients with other malignant tumors.

Design outcomes

Primary

MeasureTime frame
PSA progression-free survival;Acute genitourinary and gastrointestinal toxicity;Late genitourinary and gastrointestinal toxicity;—

Secondary

MeasureTime frame
Local progression-free survival;distant metastasis-free survival;Progression Free Survival,PFS;overall survival;prostate cancer-specific survival;—

Countries

China

Contacts

Public ContactYali Shen

West China Hospital, Sichuan University

sylprecious@163.com+86 189 8060 5780

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026